Rebiact 1.5 mg (Capsule)
Unit Price: ৳ 23.00 (3 x 10: ৳ 690.00)
Strip Price: ৳ 230.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Rivastigmine tartrate |
| Company | Genvio pharma ltd |
| Also available as |
Indications
- Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
- Symptomatic treatment of mild to moderately severe dementia in patients with Idiopathic Parkinson's disease.
Pharmacology
- Rivastigmine is a carbamate derivative that is structurally related to physostigmine.
- Reversible binding and inactivation of cholinesterase, leading to increased concentration of acetylcholine at cholinergic synapses.
- Relatively specific for brain acetylcholinesterase and butyrylcholinesterase in comparison to peripheral tissues.
Dosage
- Initial dose of Rivastigmine 1.5 mg twice a day.
- Dose titration up to 6 mg twice a day.
- Maintenance dose of 3 mg to 6 mg twice a day.
- Transdermal patch dosage ranges from 4.6 mg/24 hours to 13.3 mg/24 hours.
Administration
- Rivastigmine should be administered twice a day, with morning and evening meals.
Interaction
- Exaggerated effects with succinylcholine-type muscle relaxants during anesthesia.
- Caution with selection of anaesthetic agents.
- Possible dose adjustments or temporary cessation if needed.
- Should not be given concomitantly with other cholinomimetic substances.
- Potential interference with anticholinergic medicinal products.
Contraindications
- Contraindicated in patients with hypersensitivity to the active substance or other carbamate derivatives.
Side effects
- Commonly reported gastrointestinal adverse reactions including nausea and vomiting.
- Female patients found to be more susceptible than male patients.
Pregnancy and lactation
- Not recommended during pregnancy unless clearly necessary.
- Excreted into milk, hence not recommended for breastfeeding women.
Precautions and warnings
- Caution in patients with sick sinus syndrome or conduction defects.
- Cholinergic stimulation may increase gastric acid secretion.
- Exacerbation of urinary obstruction and seizures.
- Monitoring of body weight, especially in patients with renal impairment or mild to moderate hepatic impairment.
- May worsen symptoms in patients with asthma or obstructive pulmonary disease.
Special populations
- Increased exposure in moderate renal and mild to moderate hepatic impairment.
- Not recommended for use in children.
Overdose effects
- Most cases of accidental overdose have not been associated with clinical signs or symptoms.
- Symptoms may include nausea, vomiting, diarrhea, hypertension, hallucinations, bradycardia, and syncope.
- Recommended management in cases of asymptomatic overdose and severe nausea and vomiting.
- Use of atropine in massive overdose.
Therapeutic class
- Belongs to the therapeutic class of Drugs for Dementia.
Storage conditions
- Store in a cool and dry place, protected from light.